Scarborough warned that those making quick profits from insider knowledge of Trump's decisions are likely to face consequences from the SEC, stating, 'There are a lot of stupid people that are thinking... we can trade on inside information.'
Kalshi is rolling out a fresh set of guardrails for its sports and political betting markets, introducing measures to preemptively block politicians, athletes, and other relevant people from trading in certain markets.
I AM PLEASED TO REPORT THAT THE UNITED STATES OF AMERICA, AND THE COUNTRY OF IRAN, HAVE HAD, OVER THE LAST TWO DAYS, VERY GOOD AND PRODUCTIVE CONVERSATIONS REGARDING A COMPLETE AND TOTAL RESOLUTION OF OUR HOSTILITIES IN THE MIDDLE EAST.
Last week Kalshi grabbed headlines when it announced via a blog post from head of enforcement Bobby DeNault that it had investigated and resolved two recent incidents of insider trading, including one tied to an individual (someone working as an editor for Beast Industries) who traded around $4,000 on MrBeast YouTube videos. Kalshi suspended this person, identified as Artem Kaptur, for two years, fined him around $20,000 and reported him to the Commodity Futures Trading Commission.
His boss shut the door and said they now needed "shorter-term opportunities to make money every month or we may not survive," which Tom now sees as the moment the scoreboard reset from three years to 30 days. "It was a very ambiguous message," he says, adding that he never asked, "Are we talking about what everybody else is doing or are we going to stay within the legal or ethical guardrail?"
A former West Coast biotech CEO has just been sentenced to more than two years in federal prison for misleading investors and stealing millions of dollars, the United States Attorney's Office for the District of Maryland announced on Monday. According to court documents and news releases, 62-year-old Oregon resident Nader Pourhassan, who was once the CEO of CytoDyn, defrauded investors from 2018 to 2021 regarding the commercialization of CytoDyn's product, a monoclonal antibody called Leronlimab.